Predictors of In-Hospital Mortality Among Hospitalized Colistin-Treated Patients at a Tertiary Urology–Nephrology Referral Center
Authors:
- Viorel Dragos RaduVRViorel Dragos Radu
- Ana-Maria Raluca PaunaAPAna-Maria Raluca Pauna
- Rodica RaduRRRodica Radu
- Liliana Mititelu-TartauLiliana Mititelu-Tartau
- Alin Mihai VasilescuAlin Mihai Vasilescu
- Theodor Florin PantilimonescuTheodor Florin Pantilimonescu
- Adriana GrigorașAGAdriana Grigoraș
- Laura FloreaLFLaura Florea
- Marius Constantin MoraruMMMarius Constantin Moraru
- Liliana ChelaruLCLiliana Chelaru
- Liviu Ciprian GavrilLGLiviu Ciprian Gavril
- Roxana Florentina GavrilRGRoxana Florentina Gavril
Open Access
- 4 September 2026
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 15 (9) , 866
Abstract
Background/Objectives: Colistin is a last-resort agent against multidrug-resistant Gram-negative infections and is administered predominantly to complex, comorbid inpatients in whom mortality is high. We aimed to identify independent baseline predictors of in-hospital mortality in colistin-treated patients and to characterize temporal changes in mortality over 15 years. Methods: We conducted a retrospective cohort study of 1225 consecutive patients receiving systemic colistin between November 2009 and November 2024 at Parhon Hospital, a tertiary urology–nephrology center in Iași, Romania; independent predictors of death were identified using multivariable logistic regression restricted to variables fixed at the time of colistin initiation, reported as adjusted odds ratios (aOR) with 95% confidence intervals (CI). Results: Patients were predominantly male (60.2%), with a mean age of 65.1 ± 14.4 years; 85.6% were admitted to urology or nephrology. In-hospital mortality was 27.6%. Mortality was independently associated with acute kidney injury (aOR 3.72, 95% CI 2.76–5.01), sepsis (aOR 2.79, 95% CI 2.11–3.70), emergency admission (aOR 1.91, 95% CI 1.40–2.61), Charlson comorbidity index (aOR 1.13 per point, 95% CI 1.05–1.22), and older age (aOR 1.03 per year, 95% CI 1.02–1.04); sex was not associated. Crude mortality increased across the study period (odds ratio 1.16 per year, 95% CI 1.13–1.20) and remained elevated after adjustment for case-mix (adjusted odds ratio 1.13 per year, 95% CI 1.09–1.17). Conclusions: Acute kidney injury, sepsis, emergency admission, comorbidity burden, and age were independently associated with in-hospital death. Mortality rose progressively over 15 years, only partly explained by an increasingly severe case-mix, supporting early risk stratification of colistin recipients.Keywords
This publication has 44 references indexed in Scilit:
- Nephrotoxicity of polymyxin B and colistin sulfate in patients with multidrug-resistant gram-negative bacteria infections: a parametric time-to-event analysisInternational Journal of Clinical Pharmacy, 2025
- The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative ReviewDrugs, 2024
- Population pharmacokinetic analysis and dosing optimization of colistin sulphate in lung transplant recipients with pneumonia: A prospective studyInternational Journal of Antimicrobial Agents, 2024
- Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: A systematic review and meta-analysis of aggregated participant dataJournal of Infection, 2024
- Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020–2022International Journal of Antimicrobial Agents, 2024
- A parallel and silent emerging pandemic: Antimicrobial resistance (AMR) amid COVID-19 pandemicJournal of Infection and Public Health, 2023
- Effects of Bacterial Urinary Tract Infection on Clinical Outcome and Survival of Kidney Transplant PatientsTransplantation Proceedings, 2022
- Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injuryPharmacological Research, 2021
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016